Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.47 |
| ▸ | CASP9 | P55211 | 3/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 11/20 | 0.45 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | CASP5 | P51878 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28926979 | 0.89 | DPP4 (0.49) | CASP1CASP3CASP9CASP7BACE1 | |
| SCHEMBL28926977 | 0.89 | DPP4 (0.49) | CASP1CASP3CASP9CASP7BACE1 | |
| SCHEMBL29310042 | 0.87 | CASP1 (0.50) | CASP1CASP3CASP9CASP7BACE1 | |
| SCHEMBL4100803 | 0.87 | CASP1 (0.50) | CASP1CASP3CASP9CASP7BACE1 | |
| SCHEMBL13194679 | 0.87 | CASP1 (0.50) | CASP1CASP3CASP9CASP7BACE1 | |
| SCHEMBL1674857 | 0.87 | CASP1 (0.50) | CASP1CASP3CASP9CASP7BACE1 | |
| SCHEMBL10068454 | 0.87 | CASP1 (0.47) | CASP1CASP3CASP9CASP7BACE1 | |
| SCHEMBL31089740 | 0.85 | ENPEP (0.55) | BACE1CTSDBACE2ENPEP | |
| SCHEMBL5194261 | 0.85 | ENPEP (0.55) | BACE1CTSDBACE2ENPEP | |
| SCHEMBL19794 | 0.84 | BACE1 (0.52) | BACE1CTSDBACE2ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | claimed |
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2026-04-07 | — | — | US | disclosed |
| US-20250236841-A1 | METHODS TO ENHANCE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS CANCER IMMUNOTHERAPEUTIC PRODUCTS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS | AIVITA BIOMEDICAL INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250041302-A1 | PROLYL HYDROXYLASE DOMAIN INHIBITOR FOR TREATING HEMORRHAGIC OR BURN SHOCK | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2025-02-06 | — | — | US | disclosed |
| CN-119000835-A | Preparation method of cylindrical magnetic bio-MOF modified electrode and application of cylindrical magnetic bio-MOF modified electrode in Caspase-3 detection | 宁波大学 | 2024-11-22 | — | — | CN | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240122987-A1 | PROLYL HYDROXYLASE DOMAIN INHIBITOR TREATMENT TO IMPROVE SURVIVABILITY OF HEMORRHAGIC SHOCK | US GOV SEC ARMY (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240115649-A1 | CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| US-20240026304-A1 | Method for Producing Stem Cell Clones Suitable for Induction of Differentiation into Somatic Cells | UNIV KYOTO (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240018230-A1 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-20230234994-A1 | VASOPRESSIN-2 RECEPTOR ANTAGONIST PEPTIDES AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-07-27 | — | — | US | disclosed |
| US-20230218705-A1 | CASPASE INHIBITORS TO ENHANCE INJURY REPAIR AND TO TREAT BACTERIAL AND VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| EP-4126010-A1 | CASPASE INHIBITORS TO ENHANCE INJURY REPAIR AND TO TREAT BACTERIAL AND VIRAL INFECTIONS | The Johns Hopkins University (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-3296390-B1 | METHOD FOR PRODUCING STEM CELL CLONES SUITABLE FOR INDUCTION OF DIFFERENTIATION INTO SOMATIC CELLS | UNIV KYOTO (JP) | 2023-01-04 | — | — | EP | disclosed |
| CN-115551536-A | Caspase inhibitors for enhanced wound repair and treatment of bacterial and viral infections | 约翰斯·霍普金斯大学 | 2022-12-30 | — | — | CN | disclosed |
| US-20220354811-A1 | METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION | INST NAT SANTE RECH MED (FR) | 2022-11-10 | — | — | US | disclosed |
| US-20220347277-A1 | Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells | AIVITA BIOMEDICAL INC (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4037714-A1 | METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | AVPR2, AVPR1A, AVPR1B | CASP1 2667/4885CASP3 3971/4885CASP9 3476/4885 |
| US-20220354811-A1 | METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION | CASP4, CASP8, CD14 | CASP1 6/4885CASP3 8/4885CASP9 11/4885 |
| US-20240018230-A1 | METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE | IFNG, TNF, IL2 | CASP1 18/4885CASP3 83/4885CASP9 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.